Novartis AG
NVSEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $51,722 | $46,660 | $51,828 | $52,877 |
| % Growth | 10.8% | -10% | -2% | – |
| Cost of Goods Sold | $12,827 | $12,020 | $15,486 | $15,867 |
| Gross Profit | $38,895 | $34,640 | $36,342 | $37,010 |
| % Margin | 75.2% | 74.2% | 70.1% | 70% |
| R&D Expenses | $10,022 | $11,371 | $9,996 | $9,540 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $12,566 | $12,489 | $14,253 | $14,886 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,763 | $1,011 | -$101 | $270 |
| Operating Expenses | $24,351 | $24,871 | $27,145 | $25,321 |
| Operating Income | $14,544 | $9,769 | $9,197 | $11,689 |
| % Margin | 28.1% | 20.9% | 17.7% | 22.1% |
| Other Income/Exp. Net | -$904 | -$646 | $425 | $13,335 |
| Pre-Tax Income | $13,640 | $9,123 | $8,371 | $25,024 |
| Tax Expense | $1,701 | $551 | $1,416 | $2,119 |
| Net Income | $11,941 | $14,850 | $6,955 | $24,021 |
| % Margin | 23.1% | 31.8% | 13.4% | 45.4% |
| EPS | 5.92 | 7.63 | 3.29 | 10.73 |
| % Growth | -22.4% | 131.9% | -69.3% | – |
| EPS Diluted | 5.87 | 7.58 | 3.27 | 10.65 |
| Weighted Avg Shares Out | 2,018 | 2,077 | 2,181 | 2,243 |
| Weighted Avg Shares Out Dil | 2,035 | 2,092 | 2,197 | 2,260 |
| Supplemental Information | – | – | – | – |
| Interest Income | $551 | $436 | $389 | $71 |
| Interest Expense | $1,006 | $855 | $860 | $907 |
| Depreciation & Amortization | $6,069 | $8,835 | $6,925 | $5,441 |
| EBITDA | $20,715 | $19,518 | $15,209 | $17,168 |
| % Margin | 40.1% | 41.8% | 29.3% | 32.5% |